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Abstract 
Biological cancer therapies, such as oncolytic, or replication-selective viruses have advantages 
over traditional therapeutics as they can employ multiple different mechanisms to target and 
destroy cancers (including direct cell lysis, immune activation and vascular collapse). This has 
led to their rapid recent clinical development. However this also makes their pre-clinical and 
clinical study complex, as many parameters may affect their therapeutic potential and so de-
fining reason for treatment failure or approaches that might enhance their therapeutic activity 
can be complicated. The ability to non-invasively image viral gene expression in vivo both in 
pre-clinical models and during clinical testing will considerably enhance the speed of oncolytic 
virus development as well as increasing the level and type of useful data produced from these 
studies. Further, subsequent to future clinical approval, imaging of reporter gene expression 
might be used to evaluate the likelihood of response to oncolytic viral therapy prior to 
changes in tumor burden. Here different reporter genes used in conjunction with oncolytic 
viral therapy are described, along with the imaging modalities used to measure their ex-
pression, while their applications both in pre-clinical and clinical testing are discussed. Possible 
future applications for reporter gene expression from oncolytic viruses in the phenotyping of 
tumors and the personalizing of treatment regimens are also discussed. 
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1. Introduction  
There has been a recent burst of interest in the 
development of biological therapies for the treatment 
of diseases such as cancer, with a variety of platforms 
and therapies displaying promising early clinical re-
sults or having moved into later stage clinical testing. 
The  likelihood  that  a  number  of  these  will  receive 
approval over the next decade means that the role of 
imaging  of  reporter  gene  expression  in  their 
pre-clinical  and  clinical  applications  will  be  a  key 
factor in their future development. Here we will ex-
amine  the  role  of  imaging  in  the  development  and 
current and future applications of oncolytic viruses, 
focusing on the use of vaccinia viral vectors. 
2. Oncolytic Viruses 
A. Background 
Oncolytic viruses are cancer therapeutics based 
on viruses whose replication is restricted to malignant 
cells (Fig. 1) [1-3]. In general this tumor selectivity can 
be achieved in one of two ways; (i) some viruses that 
normally do not cause disease in humans can never-
theless replicate in cancer cells (where the interferon 
(IFN) anti-viral response is frequently non-functional) 
or  in  tumors  (where  an  immunosuppressive  envi-
ronment exists). These are typically small viruses with 
fast replication cycles, such as reovirus[4, 5], Newcas-
tle Disease Virus[6] or VSV[7]; (ii) the second group of 
oncolytic vectors are based on viruses that are either 
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used  as  vaccines  against  common  disease-causing 
viruses  (such  as  vaccinia  virus[8]  or  the  Edmonton 
strain  of  measles  virus[9])  or  on  viruses  that  them-
selves cause known disease in humans (such as ade-
novirus[10], HSV[11] or poliovirus[12]). These tend to 
be larger viruses that are amenable to genetic engi-
neering to produce or enhance their tumor selectivity. 
This  increased  selectivity  is  normally  achieved 
through the deletion of viral virulence genes that are 
redundant  for  viral  replication  in  tumor  cells.  As  a 
result viral replication is attenuated in normal tissues, 
but proceeds normally in cancer cells. Because many 
of  the  alterations  produced  in  a  cancer  cell  during 
transformation are similar  to the adaptations that a 
virus needs to induce in a cell for successful replica-
tion[13, 14], many such virulence genes exist (as wit-
nessed  by  the  oncogenic  properties  of  some  viral 
genes and the production of some cancers as a result 
of chronic viral infections). These viral gene products 
may  fit  into  one  of  several  different  categories,  in-
cluding immune modulators (that are not required in 
the  immunosuppressive  tumor  environment)[15]; 
anti-apoptotic  proteins[16];  or  inducers  of  cellular 
proliferation[17], meaning that different viral vectors 
(sometimes  even  produced  from  the  same  viral 
backbone) may target tumors based on unique or in-
dependent  tumorogenic  properties.  Additional  ap-
proaches  to  achieving  tumor-selective  replication  of 
oncolytic  viruses  have  also  met  with  some  success. 
These  include  the  use  of  tissue  or  tumor  specific 
promoters  to  drive  expression  of  an  essential  viral 
gene[18-21]; and the alteration of viral-surface recep-
tors to selectively  target ligands that are highly ex-
pressed  on  tumor  cells  or  in  the  tumor  microenvi-
ronment[22-24]. 
 
 
Figure 1. Representation of the selective targeting and tumor-selective amplification of oncolytic viral vectors, such as oncolytic vaccinia. 
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The first proposed use of replication competent 
viruses  to  treat  cancer  was  over  100  years  ago[25], 
while the first clinical trials were attempted over 60 
years ago[26]. However, it was not until our under-
standing  of  cancer  biology,  virology  and  molecular 
biology reached a point that allowed for the logical 
construction  of  viruses  with  pre-determined  tu-
mor-targeting properties some 20 years ago that the 
field of oncolytic virology really come into being[27]. 
The rapid subsequent clinical progression of an on-
colytic adenovirus (ONYX-015)[28, 29] towards Phase 
III testing reflected the early promise of the field[30, 
31], however despite proven safety, Adenovirus was 
felt to have insufficient anti-tumor effects and so re-
searchers turned to more rapidly replicating and lytic 
viruses  to  act  as  the  backbone  of  oncolytic  agents. 
Currently,  the  highly  promising  clinical  data  with 
several  of  these  second  generation  vectors  has 
re-ignited interest in the field[32-35], and it is likely 
that one or more of these viruses will be approved in 
the North American market in the next decade.  
One advantage of oncolytic viruses is that they 
are  known  to  destroy  tumors  by  several  distinct 
mechanisms, which typically do not overlap with the 
mechanisms  induced  by  traditional  therapies[8,  36, 
37]. In addition to directly destroying infected tumor 
cells as a result of infection (which also leads to am-
plification  of  viral  copies  within  the  tumor),  many 
oncolytic  vectors  can  induce  a  potent  immune  re-
sponse within the tumor. This immune response can 
overcome  localized  immune  suppression,  and  may 
even  create  an  in  situ  vaccination  effect  through 
cross-presentation of tumor associated antigens to the 
host immune response. Furthermore several viruses 
have been demonstrated to induce a robust vascular 
collapse within the tumor that is capable of destroying 
further tumor cells[38, 39]. Because oncolytic viruses 
express their genomes primarily within the tumor and 
amplify the copy numbers of their genes in the tumor 
microenvironment,  their  effects  can  be  enhanced 
through the expression of therapeutic transgenes[40, 
41]. A variety of such transgenes have been investi-
gated expressed from these vectors, including those 
encoding  cytokines,  pro-drug  converting  enzymes 
and anti-angiogenic proteins. However, another ap-
proach that has begun to be more actively explored is 
the additional expression of reporter transgenes from 
these viruses, and this will be the focus of this review. 
B. Oncolytic Vaccinia Virus 
Here we will primarily focus on oncolytic vac-
cinia virus vectors for several reasons; (i) the field of 
oncolytic viruses is too large to satisfactorily cover all 
viruses in a single review; (ii) vaccinia is one of the 
most successful of the current generation of clinical 
vectors, with highly promising Phase I and Phase II 
clinical  data  being  reported  in  melanoma[42]  and 
HCC[33], and with systemic delivery demonstrated in 
the clinic[32]; (iii) vaccinia’s large genome means that 
a variety of different oncolytic constructs have been 
reported[8].  It  is  also  capable  of  expressing  at  least 
25KB of foreign DNA[43], meaning that expression of 
multiple genes from a single vector is possible. 
Vaccinia  is  an  excellent  candidate  to  produce 
oncolytic vectors for several further reasons[44, 45], 
including (i) it has a rapid and lytic replication cycle; 
(ii) it produces a potent immune response; (iii) it has 
been extensively used in humans during the smallpox 
eradication campaign[46], meaning that contraindica-
tions  are  well  defined  and  approved  anti-virals  are 
available[47, 48]; and (iv) it has evolved to spread in 
the  vascular  system  of  the  host[49],  meaning  that 
systemic  delivery  and  spread  between  tumors  has 
been demonstrated in pre-clinical[32, 50] and clinical 
testing.  Vaccinia also has well defined molecular bi-
ology, including standard cloning techniques and a 
choice of natural and synthetic promoters[51, 52] with 
different  strengths  and  expression  patterns.  This 
means  that  viral  reporter  gene  expression  can  be 
linked to certain events, such as viral replication. 
Several  different  oncolytic  strains  of  vaccinia 
have  been  reported,  with  perhaps  the  most  widely 
studied  in  pre-clinical  models  being  vvDD[17,  50]. 
This is a version of the Western Reserve (WR) strain of 
vaccinia with deletions in the viral thymidine kinase 
gene[53]  (meaning  that  replication  is  dependent  on 
host cell TK expression, that is upregulated in most 
tumors[54]), and  in  the  viral  growth  factor  (VGF)(a 
secreted growth factor homolog that binds the EGF-R, 
inducing  proliferation  in  surrounding  cells[55],  but 
that is redundant in >80% of cancers where mutations 
in the EGF-R signaling pathway mean it is unregu-
lated). This virus has displayed significant selectivity, 
systemic delivery and robust anti-tumor potential in 
many pre-clinical models, and has recently completed 
Phase  I  clinical  testing  (Bartlett,  unpublished  data). 
However, the vaccinia strain that has been most ex-
tensively developed in the clinic is JX-594 (Jennerex, 
Inc), a version of the Wyeth strain of vaccinia with a 
single TK gene deletion and expressing GM-CSF to 
augment  its  anti-tumor  effects[56].  This  strain  dis-
played highly promising Phase I data in a small in-
tralesional trial in melanoma patients[33, 42], and in a 
Phase I study of HCC with intratumoral injection[33]. 
It has also demonstrated systemic delivery potential 
in  the  clinic  and  so  further  intravenous  trials  and 
Phase III testing are ongoing. A further vaccinia strain 
(Lister) with deletions in the viral thymidine kinase Theranostics 2012, 2(4) 
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and  the  viral  hemaglutinin  gene  has  also  been  de-
scribed in pre-clinical studies (GLV-1h68)[57, 58] and 
has  entered  clinical  testing,  although  no  clinical  re-
sults have been reported to date. 
However, in addition to these clinical strains a 
variety of additional oncolytic vaccinia vectors have 
been described in pre-clinical studies, these include a 
strain with deletion of the viral type I IFN binding 
protein (B18R) that selectively replicates in cells with 
loss of an IFN-response phenotype[15]; viruses with 
enhanced spread to treat metastatic tumors[59]; and a 
virus with deletions in the viral serpins that targets 
cells with a loss of anti-apoptotic potential[60]. Thus 
vaccinia has the capability to target different cancers 
with vectors targeted to different phenotypic proper-
ties. 
The  therapeutic  activity  of  oncolytic  vaccinia 
virus has been covered in several recent reviews [8, 
37, 61, 62] and so we will focus on non-invasice im-
aging and diagnostic applications of this vector here. 
C. Role of the Immune Response 
One of the different mechanisms that oncolytic 
viruses,  such  as  those  based  on  vaccinia,  utilize  to 
destroy their tumor targets is the induction of a potent 
immune  response  within  the  tumor.  Although  in 
some situations the immune response may limit the 
direct oncolytic potential of these vectors, it has be-
come apparent that the immune response raised by 
the virus can provide significant therapeutic benefit. 
The action of the virus in the tumor has been demon-
strated  to  overcome  localized  immune  suppression 
that is typically found within the tumor, and can even 
induce  specific  vaccination  for  relevant  tumor  anti-
gens[37, 63, 64]. In this respect, oncolytic viruses such 
as those based on vaccinia may be thought of as per-
sonalized  approaches  to  inducing  relevant  vaccina-
tion  to  help  eradicate  residual  tumor  cells  within  a 
host, and to provide memory immune surveillance for 
long term prevention of relapse. It is also likely that 
systemic measurements of the level and type of im-
mune response induced by the viral treatment may 
ultimately be used either as an early prognostic indi-
cator of therapeutic activity, or may help elucidate the 
immune properties of the tumor being treated, and so 
assist in the design of subsequent immunotherapeutic 
treatments. 
3. Applications for the imaging of oncolytic 
viruses 
Non-invasive imaging of reporter transgene ex-
pression is a powerful tool that can provide precise 
and  unique  spacio-temporal  measurements  of  viral 
replication in vivo. In preclinical models, terminal as-
says in which cohorts of animals must be sacrificed at 
multiple time points in order to track viral biodistri-
bution present numerous drawbacks, such as the ina-
bility to perform kinetic studies in one animal or the 
requirement to section the whole animal to not miss 
unexpected localizations.  Similarly, in clinical  trials, 
biopsies are also restricted to certain target organs and 
frequently involve surgery, which limits the number 
of samples available for the study. Arming oncolytic 
viruses with reporter genes that can be detected by 
imaging is an approach that can overcome these lim-
itations [65]. Furthermore, these agents can be used 
for a wide range of other applications, such as ear-
ly-stage tumor diagnosis or detection of residual dis-
ease  after  surgery.  In  this  section,  we  focus  on  the 
different transgenes that have been used for imaging 
oncolytic  viral  replication,  as  well  as  the  possible 
pre-clinical and clinical applications of these agents. 
A.  Bioluminescence imaging 
 Bioluminescence imaging exploits the emission 
of visible photons at specific wavelengths based on 
energy-dependent reactions catalyzed by luciferases 
[66]. These reactions require a substrate, and for insect 
luciferases also require ATP, magnesium and oxygen. 
The  bioluminescence  emitted  can  be  detected  and 
amplified using sensitive detection systems, revealing 
the  sites  of  luciferase  expression  and  activity.  The 
luciferase family includes a variety of photoproteins, 
such as firefly luciferase, which metabolizes luciferin 
into oxyluciferin, or Gaussia and Renilla luciferases, 
which use coelenterazine as a substrate. By virtue of 
the wavelength of light produced leading to the most 
efficient transmission through tissues and the solubil-
ity of its substrate [67], the luc luciferase from firefly 
species (Photinus) is the most commonly used lucifer-
ase for in vivo imaging. The rapid imaging of many 
animals, ease of use of the imaging instrumentation 
and inexpensive nature of bioluminescence imaging 
means that it has become a powerful research tool for 
the pre-clinical development of novel therapies. 
 The applications of bioluminescence imaging in 
biomedicine  are  extensive.    It  has  been  used  for 
tracking  bacterial pathogens  [68], to study gene ex-
pression patterns [69], to monitor tumor cell growth 
and  regression  [70],    to  determine  the  location  and 
proliferation of stem cells [71] and to track gene ex-
pression [72]. In the context of oncolytic viruses, bio-
luminiscence has been used primarily to monitor viral 
replication  in vivo  and  biodistribution  in  preclinical 
models (Fig 2). The luciferase gene has been cloned 
and  used  for  tracking  the  replication  of  oncolytic 
parvoviruses [73], adenoviruses  [74, 75], HSV-1  [76, 
77], vaccinia virus [15, 58], measles virus [78] and VSV Theranostics 2012, 2(4) 
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[79]. Furthermore, the infection  of carrier cells with 
oncolytic viruses expressing luciferase can be used to 
evaluate the biodistribution of those cells. This strat-
egy was used to evaluate the biodistribution of carrier 
CIK (Cytokine Induced Killer) cells loaded with vac-
cinia virus expressing luciferase [80] or T-cells loaded 
with measles virus [81]. 
 A  novel  and  interesting  strategy  for  a  clinical 
application of luciferase-expressing oncolytic viruses 
is  the  use  of  such  agents  to  predict  the  therapeutic 
outcome of the oncolytic therapy. In preclinical mod-
els,  Davydova  and  collaborators  demonstrated  the 
predictive  value  of  an  early-time  point  imaging  of 
adenoviral replication in tumors [82]. The in vivo lu-
ciferase bioluminescence measured 6 days after viral 
administration significantly correlated with the anti-
tumor effect observed at day 36. On the other hand, 
bioluminescence  can  also  be  used  for  revealing  the 
locations  of  primary  tumors  and  metastases  in  ani-
mals. Yu and collaborators provided evidence that an 
intravenously  delivered  oncolytic  vaccinia  virus  ex-
pressing the Renilla luciferase replicated in the tumor 
tissue and permitted the delineation of the location of 
tumors and metastases [83].  Despite the fact that lu-
ciferase  expression  and  bioluminescence  imaging 
cannot  currently  be  used  in  humans,  these  studies 
provide  proof-of-concept  that  oncolytic  viruses  ex-
pressing  clinical-friendly  imaging  systems  may  im-
prove the outcome of clinical protocols.  
B. Fluorescence imaging 
Fluorescent proteins have been extensively used 
as reporter genes in oncolytic viruses, especially for 
tracking the replication of the virus in vitro. They offer 
the possibility to image viral replication rapidly and 
inexpensively.  The  fluorescent  protein  most  com-
monly cloned into oncolytic viruses is GFP, a 27-kDa 
protein form jellyfish Aequorea victoria that fluoresces 
green  upon  illumination  with  UV  light  [84].  This 
wild-type protein and its enhanced-fluorescent form 
have been cloned into the majority of oncolytic virus-
es, including Newcastle disease virus [85], VSV [86], 
HSV-1 [87], measles [88], adenovirus [89] and vaccinia 
virus [17]. 
The use of GFP for monitoring virus replication 
within organs in living animals is limited due to very 
low tissue penetrance of GFP excitation and emission 
wavelengths (1-2 mm). To overcome this limitation, 
novel  strategies  are  being  developed,  such  as  the 
combination of fiber optic monitoring coupled with 
confocal microscopy to allow direct, rapid and sensi-
tive visualization of fluorescent signals in the brain 
[90]. However, Li and collaborators recently success-
fully  imaged  a  GFP-expressing  Newcastle  disease 
virus using a Maestro in vivo fluorescence imaging 
system  (CRi,  part  of  Caliper  Life  Sciences,  part  of 
Perkin Elmer), demonstrating the possibility of using 
this protein for in vivo imaging [91]. Despite this, the 
use of fluorescent proteins that fluoresce in the far-red 
and  near-infrared  spectrum  maximize  tissue  pene-
trance  and  minimize  the  level  of  autofluorescence. 
Proteins such as the far-red fluorescent protein Tur-
boFP635 [92] can be expressed from oncolytic viruses 
and imaged using advanced imaging methods, such 
as fluorescence molecular tomography (FMT, such as 
with the FMT2500, VisEn, part of Perkin Elmer). In 
FMT, the subject  is exposed to continuous  wave or 
pulsed light, and the emitted light is captured by de-
tectors in an imaging chamber, arranged in a spatially 
defined order [72]. A tomographic image is reconsti-
tuted after the data is mathematically processed and 
quantitative,  three-dimensional  molecular  infor-
mation can be extracted. 
 
 
Figure 2. Patterns of infection, replication and biodistribution and persistence within the tumor after intravenous delivery of oncolytic 
vaccinia (vvDD) expressing luciferase as determined by bioluminescence imaging on an IVIS200 (Xenogen, part of Caliper, now part of 
Perkin Elmer) 
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Besides  monitoring  virus  replication,  oncolytic 
viruses  expressing  fluorescent  proteins  have  been 
tested pre-clinically for a variety of putative clinical 
applications.  As  with  luciferase-expressing  viruses, 
oncolytic  viruses  expressing  fluorescent  proteins 
might also be applied to predict therapeutic outcome. 
A novel method under development is the infection of 
tissues from patients ex vivo prior to therapy in order 
to ascertain the likelihood of successful oncolytic vi-
rotherapy  [93].  Demonstrating  functionality  of  the 
oncolytic  agent  via  fluorescence  imaging  within  ex 
vivo  tissues  may  be  a  useful  bridge  between 
pre-clinical  studies  and  clinical  trials.  Alternatively, 
GFP-expressing viruses have also been proposed for 
precise surgical navigation due to its ability to infect 
and express GFP selectively in cancer cells. Kishimoto 
and collaborators used a GFP-expressing adenovirus 
for fluorescence-guided surgery in a model of intra-
peritoneal disseminated colon cancer and in a model 
of  pleural  disseminated  lung  cancer  [94].  Five  days 
after virus intraperitoneal or intrapleural administra-
tion, a fluorescence-guided laparotomy permitted the 
resection  of  disseminated  cancer  nodules,  which 
would  otherwise  be  undetectable.  Furthermore,  an 
HSV-1 expressing GFP was also used for this purpose. 
In a model of peritoneal carcinomatosis (PC), the ad-
ministration of the oncolytic virus forty-eight hours 
prior  to  surgery  allowed  the  detection  of  residual 
disease  in  8  of  13  mice  that  experienced  surgeons 
presumed complete cytoreduction [95]. Residual dis-
ease was identified in sites corresponding to patterns 
of recurrence in a published human series, highlight-
ing  the  potential  of  combining  surgery  with  vi-
rally-directed  fluorescence  imaging.  Moreover,  this 
technique  has  also  been  used  for  the  detection  of 
lymph  node  metastases.  In  a  model  of  metastatic 
melanoma, Kelly and collaborators demonstrated that 
the  administration  of  an  engineered  vaccinia  virus 
expressing  GFP  into  the  primary  tumor  resulted  in 
viral transmission to lymph nodes, infection of lym-
phatic metastases, and transgene expression that was 
reliably and easily detected [96]. The real-time fluo-
rescence detection of nodal disease was 80% sensitive 
and 100% specific for identification of sentinel node 
disease.  In  a  model  of  metastatic  breast  cancer,  the 
injection  of  a  GFP-expressing  HSV-1  directly  into 
primary breast tumors also resulted in viral transit to 
axillary lymph nodes, infection of lymphatic metas-
tases,  and  GFP  expression  [97].  This  technique  per-
mitted  the  real-time  intraoperative  identification  of 
micrometastases  otherwise  undetectable  due  to  the 
impracticality  of  performing  extensive  histologic 
analyses on a large number of resected nodes. 
 
C.  Nuclear medicine-based imaging 
 Nuclear  medicine-based  imaging  is  reliant  on 
the ability of scanners to detect and localize gamma 
ray  emission  from  the  decay  of  a  radiotracer.  The 
scanners used are highly sensitive and provide good 
spatial resolution, as well as offering the greatest po-
tential  for  translation  into  clinical  applications,  but 
require the use of more expensive cameras and radi-
oactivity during their pre-clinical development  [98]. 
The  gamma  camera,  and  PET  (Positron  Emission 
Tomography)  and  SPECT  (Single-Photon  Emission 
Computed  Tomography)  scanners  are  the  principal 
types  of  scanners  used  in  nuclear  medicine.  When 
applied  to  oncolytic  viruses  expressing  a  reporter 
transgene, viral replication can be monitored as a re-
sult of the alteration of the biodistribution of a tracer 
molecule  at  the  sites  of  expression  of  the  reporter 
gene, leading to a local concentration of the tracer at 
the site of viral replication. 
Three types of reporter gene families have been 
cloned into oncolytic viruses. In the first family, the 
accumulation of the radio-labelled substrate is based 
on enzymatic activities that trap the tracer inside tar-
get cells when phosphorylated by the enzyme. When 
working with HSV-1, the endogenous thymidine ki-
nase  can  be  used  for  this  purpose.  FIAU  and 
[18F]FHBG have been used previously as the substrate 
for HSV-TK to successfully image the viral replication 
in animal models using a PET scanner [99, 100]. Fur-
thermore,  a  Sindbis  virus  expressing  HSV-TK  was 
also  successfully  imaged  using  18F-FEAU  as  a  sub-
strate with a PET scanner [101]. However, in an at-
tempt to monitor the replication of an oncolytic HSV-1 
in  glioma  patients,  no  evidence  of  viral  replication 
was  found  using  a  123I-FIAU  brain  SPECT  scanner 
[102]. This unsuccessful result was probably due to 
limited expression of endogenous HSV-TK and lim-
ited sensitivity of 123I and SPECT imaging, indicating 
the  need  for  higher  reporter  gene  expression,  more 
potent  reporter  genes  and/or  greater  sensitivity  in 
radioisotope detection for the clinical setting.  
The  second  family  of  reporter  genes  involves 
membrane  receptors  that  bind  and  trap  a  ra-
dio-labeled  substrate.  The  human  somatostatin  re-
ceptor  SSTR2  was  successfully  used  to  monitor  the 
replication of an oncolytic vaccinia virus in mice using 
111In-pentetreotide as ligand and a gamma camera for 
the imaging [103]. Furthermore, the system dopamine 
DR2 receptor/123I-IBF or 11C-raclopride is also suitable 
for application to oncolytic viruses [104]. Finally, the 
third and most extensively examined family is that of 
membrane proteins that mediate ionic transport. The 
human norepinephrine transporter (hNES) has been 
used in the context of an oncolytic vaccinia virus to Theranostics 2012, 2(4) 
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monitor  its  replication  in  mice  [105],  but  the  most 
broadly used ion transporter used for imaging is the 
human sodium iodide symporter (hNIS). This can be 
imaged using [123, 124, 131I]NaI, [99mTc]pertechnetate, or 
[186,  188Re]perrhenate,  among  others,  and  using  scin-
tigraphy,  PET  or  SPECT  scanners  [65].  To  monitor 
viral  replication  in  preclinical  models,  it  has  been 
cloned into measles virus [106, 107], VSV [108], ade-
novirus  [109,  110],  and  vaccinia  virus  [111].  In  the 
clinical setting, the feasibility of using hNIS-mediated 
imaging was demonstrated in a phase I clinical trial 
treating  prostate  cancer  patients  with  an  oncolytic 
adenovirus  coding  for  the  hNIS  gene  [112].  In  this 
study, viral replication was detected in 7 of 9 patients 
when 1x1012 vp were injected. However, Rajecki and 
collaborators failed to image the replication of a dif-
ferent oncolytic adenovirus expressing the hNIS gene 
[113].  In  this  study,  a  cervical  metastatic  carcinoma 
patient was treated with 3x1011 vp and a SPECT-CT 
scanner was used for the imaging. The difference in 
the success of the imaging may be explained by the 
dose administrated, the virus design, and the relative 
sensitivity of PET and SPECT scanners. 
Alternative applications for the combination of 
nuclear  medicine-based  imaging  with  oncolytic  vi-
ruses  have  also  been  described.  As  with  oncolytic 
viruses expressing fluorescent proteins, the endoge-
nous thymidine kinase coded by an oncolytic herpes 
virus has been used for the imaging and detection of 
lymph node micrometastases. In a pre-clinical model 
of  metastatic  melanoma,  Brader  and  collaborators 
successfully identify 8 out of 8 tumor-positive nodes 
after an intratumoral injection of the oncolytic agent 
[114]. No overlap between radioactivity levels in tu-
mor-positive and tumor-negative lymph nodes using 
[18F]FEAU  PET  was  described.  Furthermore,  genes 
such as hNIS can be used for radiotherapy. In addi-
tion to imaging, the radiation physical crossfire effect 
permits the destruction of non-infected tumor by ra-
diation emitted from neighboring cells transduced by 
recombinant oncolytic viruses [115]. This effect is of 
relevance because it allows for the destruction of in-
tra-tumoral physical barriers such as stromal cells that 
can  otherwise  handicap  the  dispersion  of  the  virus 
throughout  the  tumor.  Importantly,  results  from 
xenograft  tumors  treated  with  an  oncolytic  measles 
virus expressing NIS showed complete regression of 
the tumor after 131I therapy [115, 116]. 
4. Future Directions 
More  extensive  use  of  clinical  imaging  of  re-
porter gene expression from oncolytic strains of vac-
cinia virus and other oncolytic backbones will be ex-
pected to validate the use of different reporter con-
structs to image viral gene expression, and to correlate 
this  with  viral  replication  patterns  and  therapeutic 
outcome, as has previously been shown in pre-clinical 
imaging models. This will allow the collection of sig-
nificantly more data during clinical evaluation of on-
colytic  vectors,  helping  advance  the  clinical  devel-
opment  of  these  therapeutics  at  a  considerably  in-
creased pace. Furthermore, as one or more of these 
vectors  may  soon  become  approved  agents  for  the 
treatments  of  some  cancers  in  the  North  American 
and European markets, the ability to image at early 
times after their application in order to provide early 
markers  of  therapeutic  activity  will  provide  signifi-
cant advantages, allowing for a more rapid switch to 
alternative therapies in the case of treatment failure. 
However,  beyond  these  basic  clinical  applica-
tions  of  imaging  of  reporter  gene  expression  from 
oncolytic viruses to assess therapeutic response and 
possibly to define the margins of the tumor and loca-
tions of metastases for surgery, it is possible to also 
envisage other uses. Because different viruses may be 
targeted to different phenotypic properties within the 
tumor, it may be possible to create a virus that would 
specifically replicate in tumors that are also sensitive 
to particular targeted therapies. In this way viral rep-
lication (and gene expression) would act as a predic-
tive marker for  the likelihood  of response to a sec-
ondary therapy. Alternatively, this may be extended 
with  the  possibility  of  producing  multiple  different 
oncolytic  vectors  (ideally  based  on  the  same  viral 
backbone), targeted through different viral gene dele-
tions  to  different  phenotypic  tumor  properties  and 
expressing different reporter genes. The simultaneous 
application of these viruses and the readout of their 
relative reporter gene expression may act as a more 
accurate  method  for  defining  the  properties  of  the 
tumor and so would act as a means to direct person-
alized  treatment  regimens.  For  example,  multiple 
vaccinia  strains  with  different  virulence  gene  dele-
tions  and  expressing  different  fluorescent  proteins 
could be applied into a single lesion of a melanoma 
patient, and an optical readout used to ‘bar-code’ the 
tumor  and  so  define  the  treatment  most  likely  to 
produce a response. Alternatively, this same approach 
may  simply  be  used  to  determine  which  oncolytic 
viral  strain  would  be  most  appropriate  to  subse-
quently treat the patient with at higher and/or sys-
temic doses.  
5. Discussion 
 The recent clinical advances with oncolytic vi-
ruses have led to a more focused interest on the ex-
pression  of  transgenes  from  within  the  therapeutic 
vectors  themselves.  Although  this  has  traditionally Theranostics 2012, 2(4) 
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involved  the  use  of  genes  that  might  increase  the 
therapeutic  activity  of  the  oncolytic  virus  (such  as 
immune modulators, toxins, or pro-drug converting 
enzymes), advances in molecular imaging have led to 
the  routine  use  of  reporter  genes  for  non-invasive 
imaging being additionally applied. This is of partic-
ular utility in larger viral agents (such as HSV-1 or 
vaccinia virus) that have the cloning capacity to ex-
press multiple reporter transgenes).  
 The  benefits  of  reporter  gene  expression  and 
non-invasive molecular imaging in pre-clinical mod-
els include more rapid and extensive descriptions of 
viral  biodistribution  and  persistence  of  replication 
under different conditions. However, it is in the clin-
ical application of reporter gene expression that the 
greatest benefits may ultimately be witnessed. These 
are  likely  to  include  early  indicators  of  viral  thera-
peutic activity and even as a means to locate tumor 
margins and the locations of metastases. It is  likely 
that, at least initially, PET and SPECT imaging will be 
predominantly used in the clinic. This opens up the 
possibility of additionally applying radioisotopes that 
have therapeutic rather than imaging properties. 
 Finally, the ability to target viral oncolytic vec-
tors  to  the  tumor  through  different  gene  deletions, 
and so target different phenotypic properties of the 
tumor may also allow for the phenotyping of the tu-
mor, leading to additional personalized medicine ap-
plications in tumor therapy. 
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